Glucagon‐like peptide‐1 receptor agonist‐based agents and weight loss composition: Filling the gaps

Abstract Excess adiposity is at the root of type 2 diabetes (T2D). Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have emerged as first‐line treatments for T2D based on significant weight loss results. The composition of weight loss using most diets consists of <25% fat‐free mass (FFM) loss, with the remainder from fat stores. Higher amounts of weight loss (achieved with metabolic bariatric surgery) result in greater reductions in FFM. Our aim was to assess the impact that GLP‐1RA‐based treatments have on FFM. We analysed studies that reported changes in FFM with the following agents: exenatide, liraglutide, semaglutide, and the dual incretin receptor agonist tirzepatide. We performed an analysis of various weight loss interventions to provide a reference for expected changes in FFM. We evaluated studies using dual‐energy X‐ray absorptiometry (DXA) for measuring FFM (a crude surrogate for skeletal muscle). In evaluating the composition of weight loss, the percentage lost as fat‐free mass (%FFML) was equal to ΔFFM/total weight change. The %FFML using GLP‐1RA‐based agents was between 20% and 40%. In the 28 clinical trials evaluated, the proportion of FFM loss was highly variable, but the majority reported %FFML exceeding 25%. Our review was limited to small substudies and the use of DXA, which does not measure skeletal muscle mass directly. Since FFM contains a variable amount of muscle (approximately 55%), this indirect measure may explain the heterogeneity in the data. Assessing quantity and quality of skeletal muscle using advanced imaging (magnetic resonance imaging) with functional testing will help fill the gaps in our current understanding.